For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
CagriSema is a fixed-dose combination of cagrilintide 2.4 mg (long-acting amylin analogue) and semaglutide 2.4 mg (GLP-1 receptor agonist), once weekly subcutaneous. REDEFINE 1 (n=3,417, 68 weeks): 20.4% weight loss (ITT) vs 3.0% placebo, exceeding semaglutide alone (14.9%) by 5.5 points. REDEFINE 2 (n=1,206, T2D): 15.7% weight loss. REDEFINE 4 head-to-head vs tirzepatide 15 mg (n=809, 84 weeks, open-label): CagriSema 23% vs tirzepatide 25.5%, noninferiority not met. NDA filed December 2025, decision expected late 2026. If approved, would be the first GLP-1/amylin combination product.
CagriSema is a not-yet-approved pharmaceutical product under NDA review by the FDA. It is not a research peptide. Its inclusion in this series reflects its position as the most advanced fixed-dose combination in the obesity pharmacotherapy space and because understanding how combining two distinct peptide mechanisms (GLP-1 plus amylin) changes weight loss outcomes is directly relevant to how readers evaluate the broader peptide landscape.
The separate cagrilintide profile on this site covers the amylin component as a standalone molecule. This profile covers CagriSema as the combination product, because the combination is what is being submitted for approval and the combination data tell a story that neither component tells alone.
The most important caveat: CagriSema's clinical positioning depends heavily on what question you ask. Against placebo, it produces approximately 20% weight loss, superior to semaglutide alone (14.9%) and among the highest published for any GLP-1-based product. Against tirzepatide in a head-to-head trial, it did not demonstrate noninferiority (23% vs 25.5% at 84 weeks, open-label). The competitive landscape in obesity is moving extremely fast, and a product that would have been best-in-class in 2022 may be positioned differently by the time it launches.
CagriSema combines two peptide mechanisms in a single once-weekly injection. Semaglutide 2.4 mg is the same GLP-1 receptor agonist used in Wegovy, already FDA-approved for weight management, with established efficacy producing approximately 15% weight loss. Cagrilintide 2.4 mg is a long-acting synthetic amylin analogue (Dual Amylin and Calcitonin Receptor Agonist, DACRA) with a half-life of approximately 160 to 195 hours enabling once-weekly dosing.
The combination rationale is pharmacological synergy: semaglutide and cagrilintide suppress appetite through different receptor systems in the brainstem and hypothalamus. Semaglutide acts primarily through GLP-1 receptors in the hypothalamic arcuate nucleus and area postrema. Cagrilintide acts through amylin/RAMP receptor complexes in overlapping but distinct brainstem circuits, adding a separate satiety signal. REDEFINE 1 confirmed additive benefit: the combination (20.4%) exceeded semaglutide alone (14.9%) and cagrilintide alone (11.8%).
Novo Nordisk developed CagriSema as its next-generation obesity product. The REDEFINE clinical program encompasses 11+ trials including two pivotal trials (approximately 4,600 adults), a head-to-head against tirzepatide (809 adults), a 7,000-patient cardiovascular outcomes trial (REDEFINE 3), and planned higher-dose evaluations. Cagrilintide's structural design was described by Larsen et al. (2021, Journal of Medicinal Chemistry), with cryo-EM receptor binding studies published in Nature Communications (2025).
CagriSema's mechanism derives from simultaneous activation of two distinct peptide receptor systems.
GLP-1 receptor activation (semaglutide component): GLP-1R in the hypothalamic arcuate nucleus and area postrema mediates appetite suppression and reduced caloric intake. Pancreatic GLP-1R activation drives glucose-dependent insulin secretion and glucagon suppression. GI tract GLP-1R activation delays gastric emptying. These are the same mechanisms as approved Wegovy.
Amylin and calcitonin receptor activation (cagrilintide component): amylin receptors (heterodimers of the calcitonin receptor with RAMP1, RAMP2, or RAMP3) in the area postrema and nucleus of the solitary tract produce a separate satiety signal that reduces meal size and suppresses postprandial glucagon. Cagrilintide also activates the calcitonin receptor directly (DACRA profile), which may contribute additional metabolic effects including potential bone-protective properties.
The synergy hypothesis: semaglutide and cagrilintide suppress appetite through different receptor populations with different downstream signaling pathways, producing meaningful additive appetite suppression. The REDEFINE 1 data confirm this: the combination exceeded either monotherapy by 5.5 to 8.6 percentage points. This pharmacological principle, combining distinct receptor-mediated satiety pathways for additive effect, represents a key trajectory in obesity drug development.
In REDEFINE 1, CagriSema produced mean weight loss of 20.4% (ITT) and 22.7% (trial product estimand) vs 3.0% placebo at 68 weeks. 91.9% achieved at least 5% weight loss (vs 31.5% placebo), 60% achieved at least 20%, and 40.4% achieved at least 25%. Semaglutide alone achieved 14.9% and cagrilintide alone achieved 11.8%, establishing that both components contribute and that the combination exceeds either monotherapy by a clinically meaningful margin. Quality of life improvements were significant on IWQOL-Lite-CT and SF-36 physical function.
In REDEFINE 4 (open-label, 84 weeks, n=809), CagriSema achieved 23.0% weight loss (if-all-adhere) and 20.2% (treatment-regimen estimand), compared to 25.5% and 23.6% with tirzepatide 15 mg. CagriSema did not meet the primary endpoint of noninferiority against tirzepatide. The open-label design introduces potential bias. The result does not establish inferiority in absolute terms, but superiority or equivalence to tirzepatide was not demonstrated.
CagriSema has the most complete Phase 3 dataset of any first-in-class amylin combination product. The 20.4% weight loss (ITT) positions it above semaglutide monotherapy and is clinically meaningful by any threshold. However, the REDEFINE 4 head-to-head failure against tirzepatide complicates its competitive positioning. The FDA decision, expected by late 2026, will be based on the REDEFINE 1 and 2 placebo-controlled data rather than the head-to-head comparison.
In REDEFINE 2, CagriSema produced 15.7% mean weight loss vs 3.1% placebo at 68 weeks. 89.7% achieved at least 5% weight loss vs 30.3% placebo. HbA1c reductions were clinically significant. The weight loss in T2D is approximately 5 percentage points less than the 20.4% achieved in the non-diabetic REDEFINE 1 population, consistent with the established pattern that metabolic disease attenuates pharmacological weight loss.
In the Phase 2 T2D trial, CagriSema reduced HbA1c by 2.2 percentage points and body weight by 15.6%, showing superiority over either component alone.
CagriSema produces meaningful weight loss and glycemic improvement in T2D, with attenuation compared to the non-diabetic population. The T2D data are included in the NDA filing. Whether the cagrilintide component adds glycemic benefit beyond semaglutide is biologically plausible but not independently quantified in the combination trial design.
In the open-label REDEFINE 4 trial, CagriSema achieved 23.0% weight loss (if-all-adhere) vs 25.5% for tirzepatide 15 mg at 84 weeks. Under the treatment-regimen estimand: 20.2% vs 23.6%. The primary endpoint of noninferiority was not met under either estimand. GI adverse events were mild-to-moderate for CagriSema, consistent with GLP-1 class.
The open-label design is a significant caveat: participants and investigators knew which drug was administered, potentially influencing adherence and reporting. However, the numerical difference was consistent across both estimands. Novo Nordisk is pursuing higher-dose CagriSema (2.4/7.2 mg) Phase 3 trials to explore whether increasing the semaglutide component closes the gap.
REDEFINE 4 is an important and sobering result. CagriSema produces substantial weight loss but tirzepatide at maximum dose produces more. This does not prevent CagriSema from gaining approval (the NDA rests on placebo-controlled data), but it shapes competitive positioning. The planned higher-dose trials suggest Novo Nordisk recognizes the gap and is working to address it.
REDEFINE 3 is ongoing and has not reported results. The trial is designed to determine whether CagriSema reduces major adverse cardiovascular events in adults with established CVD. The semaglutide component has independent CV benefit data from the SELECT trial (20% MACE reduction). Whether the cagrilintide component adds cardiovascular benefit beyond semaglutide is unknown. No interim data are available.
Cardiovascular outcomes data will be critical for CagriSema's long-term positioning and insurance coverage. Semaglutide already has proven CV benefit via SELECT; the incremental contribution of cagrilintide to cardiovascular risk reduction remains an open question that REDEFINE 3 is designed to answer.
Meta-analytic data comparing GLP-1 agonists to cagrilintide-based therapy suggest cagrilintide has a lower odds ratio for nausea and vomiting than semaglutide or liraglutide at comparable weight loss levels. In the Phase 2 trial, GI events with cagrilintide 2.4 mg monotherapy were substantially lower than at the maximum-studied 4.5 mg dose. In REDEFINE 1, the combination GI rate (79.6%) was largely attributable to the semaglutide component.
The practical implication: for patients who tried semaglutide and stopped due to vomiting, cagrilintide monotherapy (once approved) may offer meaningful weight loss via a mechanistically distinct pathway with potentially better GI tolerability. That hypothesis has not been directly tested in a tolerability-enriched trial.
The tolerability differentiation case is mechanistically plausible and directionally supported by meta-analytic comparisons, but it has not been directly tested in patients selected for GLP-1 intolerance. The CagriSema combination includes semaglutide, so the tolerability advantage applies primarily to the cagrilintide monotherapy scenario rather than the combination product.
CagriSema is a fixed-dose combination in a single pre-filled pen delivering cagrilintide 2.4 mg and semaglutide 2.4 mg per injection. Dose escalation follows a 16-week protocol titrating both components in parallel. The fixed-dose design means patients cannot independently adjust the amylin or GLP-1 component. This is a pharmaceutical product under NDA review, not a research peptide. It is not available for purchase and cannot legally be compounded. All dosing data come from Phase 3 trials enrolling approximately 4,600 adults.
CagriSema vs semaglutide (Wegovy): same GLP-1 dose plus amylin component adds approximately 5.5 percentage points of weight loss. Vs tirzepatide (Zepbound): numerically less weight loss in head-to-head (23% vs 25.5%), noninferiority not met. Vs retatrutide: different mechanism (GLP-1/amylin vs triple GLP-1/GIP/glucagon), competitive data pending Phase 3. CagriSema is the only combination product with Phase 3 data and an NDA filed. See the separate cagrilintide profile for monotherapy data and the amylin mechanism in detail.
The safety profile of CagriSema reflects the combined adverse event burden of both components.
Gastrointestinal adverse events are the dominant safety signal. In REDEFINE 1, GI adverse events occurred in 79.6% of CagriSema patients vs 39.9% with placebo. Nausea, diarrhea, and vomiting were most common, predominantly mild-to-moderate and mainly during the 16-week dose escalation phase. Treatment discontinuation due to adverse events was approximately 1%. Meta-analytic comparisons suggest cagrilintide may produce less vomiting than GLP-1 agonists alone, but the CagriSema combination GI rate is largely attributable to the semaglutide component.
Injection site reactions occurred at higher rates with CagriSema than placebo, generally mild and transient. Anti-cagrilintide antibodies developed in 46% to 73% of participants by week 26 in Phase 2 studies but did not appear to reduce efficacy or cause severe allergic reactions.
Boxed Warning for semaglutide (applies to CagriSema): thyroid C-cell tumors in rodent studies. Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2. Calcitonin receptor activity from the cagrilintide component raises theoretical concerns regarding possible malignancy risk, based on historical regulatory scrutiny of nasal calcitonin products. Long-term post-marketing surveillance will be required.
Pancreatitis, gallbladder disease, and acute kidney injury are class-level concerns from the semaglutide component, consistent with GLP-1 receptor agonist labeling.
CagriSema represents the pharmacological principle of combining two distinct peptide mechanisms for additive weight loss: GLP-1 receptor agonism (semaglutide) plus amylin receptor agonism (cagrilintide). The REDEFINE program has generated the most complete Phase 3 dataset for any first-in-class amylin combination, and if approved it would be the first GLP-1/amylin combination product on the market.
The honest assessment: CagriSema is a strong product with a positioning problem. Against placebo, the 20% weight loss is clinically impressive and clearly exceeds semaglutide alone. Against tirzepatide at its maximum dose, it came up short. Against retatrutide (not yet approved but with 24% Phase 2 weight loss), the competitive gap may widen further.
The question for readers: does the dual mechanism offer differentiated value beyond raw weight loss magnitude? Possible answers include better tolerability for GI-sensitive patients, potential bone-protective effects from calcitonin receptor activation, and the value of a mechanistically distinct combination. These remain hypotheses requiring dedicated investigation.
Novo Nordisk is pursuing higher-dose formulations (CagriSema 2.4/7.2 mg) and longer-duration studies (REDEFINE 11) designed to assess CagriSema's full weight-loss potential. Whether that potential closes the gap with tirzepatide is the central competitive question the next wave of data will answer.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use